Bacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051

By |2020-12-03T17:11:29+00:00December 3rd, 2020|

Bacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051, a Novel Therapeutic Approach to Treat Inflammatory Diseases Such As Ulcerative Colitis -- BT051, a gut-restricted drug which is designed to target neutrophil migration and subsequent activation, was shown to be safe and well tolerated. CONCORD, Mass. [...]